Sarissa Capital Has Commenced the Process to Call a Special Meeting of Amarin Shareholders to Remove and Replace Certain Board Members
Sarissa Capital Management has expressed concerns over Amarin Corporation's management, urging immediate representation on the board to restore shareholder value. Sarissa highlighted that shareholders have lost over
- Sarissa is the largest shareholder, indicating substantial investment and interest in restoring value.
- Sarissa has a successful track record in turning around struggling healthcare companies.
- Amarin's stock has fallen 64% year-to-date, leading to a loss of over
$850 million for shareholders. - The board's delay in addressing shareholder concerns reflects poor governance and lack of urgency.
Sarissa believes Amarin risks destroying additional shareholder value unless Sarissa representatives are immediately added to the board
Amarin board’s governance process lacks urgency and disregards shareholder vote at annual meeting
Amarin’s board seems to be trying to outdo the misguided leadership of the Roman Emperor Nero who played his lyre while
This year alone, Amarin shareholders have lost over
Sarissa, the largest shareholder of Amarin and a sophisticated institutional investor with a long history of shareholder value creation in healthcare companies, wants to help restore lost value and guide the company through this critical period. We fear that the continued mismanagement of the business will result in further permanent destruction of shareholder value. We believe Amarin’s current trajectory risks the company running out of cash and will result in the need to raise capital at a terrible valuation, severely diluting existing shareholders and further destroying shareholder value.
As we have heard from many shareholders, Amarin appears to not share our collective sense of urgency. Sarissa has discussed with the company adding shareholder representatives to the board for many months, but the board appears to be running a dawdling process that seems to ignore the critical period facing the company. Even after the clear and loud vote by shareholders in June, the directors on Amarin’s board took more than twelve weeks to interview Sarissa board candidates, seemingly unable to prioritize the company over their summer schedules while destroying further shareholder value. The drawn-out process appears to us to embody the company’s lackadaisical and reactive management of shareholder capital.
We cannot stand idly by as the board and management continue to risk destroying further shareholder value and potentially make the business increasingly unsalvageable. Sarissa has a history of helping struggling healthcare companies, including in the cardiovascular space, such as The Medicines Company. In order to turn the company around, we believe Sarissa representatives must be added to the board immediately. Although we will continue our discussions with the company, we have commenced the process to call a special meeting of shareholders to remove and replace certain Amarin directors who we believe do not serve the interest of shareholders. We hope that this process will ultimately be unnecessary and that the board will act swiftly to appoint our representatives to the board. However, given how reactive and drawn out the board process has been to date, we have little optimism that the board will now act with necessary and sufficient urgency.
*Calculated from end of day
†Calculated from end of day
###
CERTAIN INFORMATION CONCERNING THE PARTICIPANTS
SARISSA STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC’S WEB SITE AT WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS’ PROXY SOLICITOR.
The anticipated participants in the proxy solicitation include Sarissa and Dr.
As of the date hereof, Sarissa and
View source version on businesswire.com: https://www.businesswire.com/news/home/20221011005498/en/
Jean Puong
info@sarissacap.com
Source:
FAQ
What is Sarissa Capital's stance on Amarin's board of directors?
How much value have Amarin shareholders lost in 2022?
What actions is Sarissa Capital planning regarding Amarin's management?
Why is Sarissa Capital worried about Amarin's financial future?